Siemens Healthineers AG, trading under the symbol OTC:SMMNY, is a leading global medical technology company. It specializes in imaging, diagnostics, and advanced therapies, providing innovative solutions to healthcare providers. The company competes with other major players in the medical technology sector, such as GE Healthcare and Philips.
On February 5, 2026, SMMNY reported earnings per share of $0.28, surpassing the estimated $0.27. The company also reported revenue of approximately $6.37 billion, exceeding the estimated $5.29 billion. This strong financial performance is attributed to robust margin performance in its core imaging and cancer-care units, as highlighted by Seeking Alpha.
Despite challenges in its diagnostics business and adverse currency exchange rates, Siemens Healthineers managed to deliver a strong operating profit. The company's price-to-earnings (P/E) ratio is approximately 43.17, indicating that investors are willing to pay over 43 times the company's earnings per share. This suggests a high level of investor confidence in the company's future growth prospects.
The price-to-sales ratio stands at about 3.97, suggesting that the market values the company at nearly four times its annual sales. Additionally, the enterprise value to sales ratio is approximately 4.61, reflecting the company's total valuation relative to its sales. These metrics indicate a strong market valuation for Siemens Healthineers.
The enterprise value to operating cash flow ratio is around 34.71, indicating the company's valuation in relation to its cash flow from operations. The earnings yield is approximately 2.32%, providing insight into the return on investment. With a debt-to-equity ratio of about 0.83 and a current ratio of approximately 1.11, Siemens Healthineers demonstrates a moderate level of debt and good short-term financial health.
